trial

Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)

NCTId NCT00145496
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 468 (actual)
Sponsored by Organon and Co
Primary completion 2008-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
468 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2004-12
Primary completion
2008-11
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
AsenapineOlanzapine

Sponsors

Organon and CoLead Sponsor

Sites

0 total

Linked catalysts

1
Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persi — primary completion2008-11

Facts & assertions

4 sourced
Enrollment
468
Phase
PHASE3
Primary Completion Date
2008-11
Status
COMPLETED
relationships
The graph out of here
drug
Asenapine
drug
Olanzapine
drug
lead_sponsor
Organon and Co
company
indication
Schizophrenia
indication
Schizophrenia
indication